SEC Comment Letter 0000000000-23-014072 to Innate Pharma SA (IPHA, IPHYF) (CIK 0001598599) (IPHA)
Innate Pharma SA (IPHA, IPHYF) (CIK 0001598599)
Date: Dec. 26, 2023 · CIK: 0001598599 · Accession: 0000000000-23-014072
AI Filing Summary & Sentiment
File numbers found in text: 333-276164
Letter
United States securities and exchange commission logo December 26, 2023 Claire de Saint Blanquat Vice President, Legal & Corporate Innate Pharma SA 117 avenue de Luminy 13009 Marseille, France Re:Innate Pharma SA Registration Statement on Form F-3 Filed December 20, 2023 File No. 333-276164 Dear Claire de Saint Blanquat: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Linda Hesse
Show Raw Text
United States securities and exchange commission logo
December 26, 2023
Claire de Saint Blanquat
Vice President, Legal & Corporate
Innate Pharma SA
117 avenue de Luminy
13009 Marseille, France
Re:Innate Pharma SA
Registration Statement on Form F-3
Filed December 20, 2023
File No. 333-276164
Dear Claire de Saint Blanquat:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Linda Hesse